UnitedHealth Crushes Q2 Estimates, Lifts 2026 Profit View on Cost Control
UNH sits 78% above its 52-week low of $234.6.
Summary
UnitedHealth reported Q2 adjusted EPS of $6.38, smashing the $4.90 consensus, and raised its 2026 adjusted EPS guidance to $19.50-$20.00 from at least $17.75. The beat was driven by a medical cost ratio of 86.70%, well below the 88.47% estimate, and a 29% jump in Optum operating income to $4 billion. Revenue of $112 billion also topped estimates, though the company maintained its full-year revenue outlook at $439 billion. This follows a mixed Q1 and a $2B buyback announced in April; the sharp margin improvement and guidance hike signal the turnaround under CEO Hemsley is gaining traction faster than expected. The stock is trading near its 52-week high, and this report could push it toward that level.
At the time of this announcement, UNH was trading at $417.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $380.1B. The 52-week trading range was $234.60 to $434.30. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.